Previous studies have shown that fibromyalgia is associated with reductions in gray matter in parts of the brain, but the exact cause is not known. Using sophisticated brain imaging techniques, researchers from Louisiana State University, writing in the June 2009 issue of The Journal of Pain,* found that alterations in levels of the neurotransmitter dopamine might be responsible for gray matter reductions.
For the study, magnetic imaging resonance data from 30 female fibromyalgia patients were compared with 20 healthy women of the same age. The primary objective of the study was to confirm original findings about reduced gray matter density in a larger sample of fibromyalgia patients. They explored whether there is a correlation between dopamine metabolic activity and variations in the density of gray matter in specific brain regions.
• Results showed there were significant gray matter reductions in the fibromyalgia patients, which supports previous research.
• In addition, the fibromyalgia patients showed a strong correlation of dopamine metabolism levels and gray matter density in parts of the brain in which dopamine controls neurological activity.
The authors concluded that the connection between dopamine levels and gray matter density provide novel insights into a possible mechanism that explains some of the abnormal brain morphology associated with fibromyalgia.
1. See “Changes in Gray Matter Density in Fibromyagia: Correlation with Dopamine Metabolism,” by Patrick B Wood, Michael F Glabus, Ryan Simpson, and James C Patterson 2nd, Louisiana State University Health Sciences Center, Shreveport, LA, USA. [E-mail: email@example.com]
Note: To read another recent article by Patrick B Wood, MD, and Andrew J Holman, MD, originators of the Dopamine Theory of Fibromyalgia, see "An Elephant Among Us: The Role of Dopamine in the Pathophysiology of Fibromyalgia" published Feb 2009 in The Journal of Rheumatology.
Source: American Pain Society news release, Jun 16, 2009